User:Noodlemaz/Mark Caulfield

Professor Mark Caulfield, FMedSci, is is a British cardiovascular researcher. He is Co-director of the William Harvey Research Institute, part of the Queen Mary University of London School of Medicine and Dentistry.

Education and Career
Professor Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme covering the molecular genetics of hypertension and translational clinical research.

Since 2008 he has directed the Barts National Institute for Health Research Cardiovascular Biomedical Research Unit. He was appointed Director of William Harvey Research Institute (WHRI) in 2002 and was elected to the Academy of Medical Sciences in 2008 and was President of the British Hypertension Society (2009-2011). He is an NHS consultant in the Barts Blood Pressure Clinic within the Barts/William Harvey European Society of Hypertension Centre of Excellence. He raised £25m toward the William Harvey Heart Centre which created a translational clinical research centre and was the academic leader that created the Barts Heart Centre bringing 3 hospitals together at Barts in 2015 to create the UK’s largest heart centre (includes UCLH Heart Hospital, the London Chest Hospital and Barts). He served on the 2011 NICE Guideline Group for hypertension and Chairs the Joint UK Societies’ Working Group and Consensus on Renal Denervation for Hypertension.

In 2013 he was appointed Chief Scientist for Genomics England, charged with delivery of the 100,000 Genomes Project - whole genome sequencing of an array of rare disease and cancer samples given by participants and their families in the NHS who consent to take part. The Chief Scientist leads on all scientific activities, working with NHS scientific teams and the wider public to promote, explain, generate and maintain support for the Project. Professor Caulfield also oversees the Genomics England Clinical Interpretation Partnership (GeCIP) research programme.

Research
Caulfield's major research responsibilities at the WHRI lie within three cardiovascular themes: Translational Pharmacology & Therapeutic Innovation; Genomics & Stratified Medicine; Experimental Medicine & Pharmacology.

The Institute's WTCCC paper in Nature in 2007 was voted the Best Scientific Research Paper in the World by editors of both Nature and Science [REF], their discovery of blood pressure genes in 2009 was voted a "top 10 advance in cardiovascular research" by the American Heart Association in 2009 [REF], and their Nature paper reporting 16 genes influencing blood pressure [Nat Genet 2011?] was voted a "top 5 advance in cardiovascular research" by the American Heart Association in 2011 [REF].

In 2014 he became one of the top 200 most highly cited researchers in the world in genomics according to Thomson Reuters.

[summarise these and reference?]

Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, then 60 co-authors then Colhoun HM, Hitman G, Krauss RM, Wouter Jukema J*, Caulfield MJ*. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014 Oct 28;5:5068. doi: 10.1038/ncomms6068.

Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases:

lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014 May 31;383(9932):1899-911. doi: 10.1016/S0140-6736(14)60685-1.

Kottgen A*, then  co-authors then Caulfield M*, Bochud M*, Geiger C*. Multiple Novel Loci Highlighting Metabolic Control of Urate Production and Excretion are Associated with Gout. Nature Genetics 2013. Feb;45(2):145-54. doi: 10.1038/ng.2500. Epub 2012 Dec 23.

Georg B. Ehret*, then 346 co-authors then Bruce M. Psaty*, Gonçalo R Abecasis*, Aravinda Chakravarti*, Paul Elliott*, Cornelia M. van Duijn*, Christopher Newton-Cheh*#, Daniel Levy*##, Mark J. Caulfield*##, Toby Johnson*. Genetic variants from novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478 (7367):103-9. Voted top 5 paper in CV research and number 1 in stroke by the American Heart Association.

Louise V Wain*, then 248 co-authors- then Mark J Caulfield*, Dabeeru C Rao*, Martin D Tobin*#, Paul Elliott*#, Cornelia M van Duijn*#. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nature Genetics 2011; 43(10):1005-11.

Caulfield MJ, et al. (2008) SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008;  5(9): e197.

Barter PJ, Caulfield M, etal. Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine. 2007 Nov 22;357(21):2109-22.

Awards and Honours
In 2007, 2009 and 2011 his research has been independently rated amongst the top ten scientific discoveries in his field. In 2009 he won the Lilly Prize for Leadership in Clinical Pharmacology given by the British Pharmacological Society. He received the Genome Valley Excellence Award in 2015 at the BioAsia conference and in 2016 the Björn Folkow Award from the European Society of Hypertension.